S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
NASDAQ:NYMX

Nymox Pharmaceutical Stock Forecast, Price & News

$1.58
+0.04 (+2.60%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.54
$1.60
50-Day Range
$1.46
$2.15
52-Week Range
$1.25
$3.50
Volume
8,090 shs
Average Volume
253,035 shs
Market Capitalization
$130.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.42
30 days | 90 days | 365 days | Advanced Chart
Receive NYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.


Nymox Pharmaceutical logo

About Nymox Pharmaceutical

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

Headlines

Financial Review: Nymox Pharmaceutical (NYMX) and Its Competitors
November 25, 2021 |  americanbankingnews.com
Contrasting Nymox Pharmaceutical (NYMX) and Its Rivals
November 19, 2021 |  americanbankingnews.com
Nymox Pharmaceutical (NYMX) & Its Rivals Financial Analysis
November 16, 2021 |  americanbankingnews.com
Comparing Nymox Pharmaceutical (NYMX) & Its Competitors
November 14, 2021 |  americanbankingnews.com
Analyzing Nymox Pharmaceutical (NYMX) and The Competition
November 14, 2021 |  americanbankingnews.com
Analyzing Nymox Pharmaceutical (NYMX) & The Competition
November 13, 2021 |  americanbankingnews.com
Critical Comparison: Nymox Pharmaceutical (NYMX) and Its Competitors
November 11, 2021 |  americanbankingnews.com
Nymox Pharmaceutical (NYMX) versus Its Competitors Critical Review
November 10, 2021 |  americanbankingnews.com
Reviewing Nymox Pharmaceutical (NYMX) and Its Competitors
November 9, 2021 |  americanbankingnews.com
Head-To-Head Survey: Nymox Pharmaceutical (NYMX) vs. Its Rivals
November 9, 2021 |  americanbankingnews.com
NYMOX Provides Current Update
October 11, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NYMX
Employees
3
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.03 per share

Profitability

Net Income
$-11.74 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
37,895,000
Market Cap
$130.16 million
Optionable
Optionable

Company Calendar

Last Earnings
11/14/2014
Today
11/26/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
4/04/2022

MarketRank

Overall MarketRank

1.21 out of 5 stars

Medical Sector

1192nd out of 1,392 stocks

Diagnostic Substances Industry

20th out of 25 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions

How has Nymox Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Nymox Pharmaceutical's stock was trading at $2.29 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NYMX stock has decreased by 31.0% and is now trading at $1.58.
View which stocks have been most impacted by COVID-19
.

When is Nymox Pharmaceutical's next earnings date?

Nymox Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Nymox Pharmaceutical
.

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) released its quarterly earnings data on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter.
View Nymox Pharmaceutical's earnings history
.

Who are Nymox Pharmaceutical's key executives?

Nymox Pharmaceutical's management team includes the following people:
  • Paul Averback, Chairman, President & Chief Executive Officer
  • Randall J. Lanham, COO, Secretary, Director & General Counsel
  • Erik Danielsen, Chief Financial Officer
  • Russell I. Thomson, Vice President-Quality & Regulatory Affairs

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC).

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

Who are Nymox Pharmaceutical's major shareholders?

Nymox Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include Private Advisor Group LLC (0.21%), BlackRock Inc. (0.17%), Millennium Management LLC (0.08%), Geode Capital Management LLC (0.06%), Patriot Financial Group Insurance Agency LLC (0.04%) and Goldman Sachs Group Inc. (0.03%).
View institutional ownership trends for Nymox Pharmaceutical
.

Which institutional investors are selling Nymox Pharmaceutical stock?

NYMX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Goldman Sachs Group Inc., BlackRock Inc., and Patriot Financial Group Insurance Agency LLC.
View insider buying and selling activity for Nymox Pharmaceutical
or view top insider-selling stocks.

Which institutional investors are buying Nymox Pharmaceutical stock?

NYMX stock was acquired by a variety of institutional investors in the last quarter, including Private Advisor Group LLC, Advisor Group Holdings Inc., and Geode Capital Management LLC.
View insider buying and selling activity for Nymox Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $1.58.

How much money does Nymox Pharmaceutical make?

Nymox Pharmaceutical has a market capitalization of $130.16 million. The biopharmaceutical company earns $-11.74 million in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does Nymox Pharmaceutical have?

Nymox Pharmaceutical employs 3 workers across the globe.

What is Nymox Pharmaceutical's official website?

The official website for Nymox Pharmaceutical is www.nymox.com.

Where are Nymox Pharmaceutical's headquarters?

Nymox Pharmaceutical is headquartered at BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The biopharmaceutical company can be reached via phone at (800) 936-9669, via email at [email protected], or via fax at 514-332-2227.


This page was last updated on 11/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.